Thrombophilia Assessment Under DOAC: Effectiveness of Activated Charcoal

Recruiting

• Conditions: Thrombophilia

• Registration Number: NCT06171984
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

Direct oral anticoagulants (DOAC) are anticoagulant molecules that act either directly on factor Xa (Apixaban, Rivaroxaban) or on factor IIa (Dabigatran).

AODs interfere with most coagulation tests, especially those performed by chronometric technique.

For this reason, part of the thrombophilia workup (protein S, search for lupus anticoagulants, antithrombin for patients on dabigatran) cannot be performed on DOACs at the HUS.

Recent studies have highlighted the effectiveness of activated charcoal to adsorb DOACs in order to perform certain hemostasis tests.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-07-19
• Study First Submitted: 2022-09-06
• Status Verified: 2023-12
• Study First Submitted QC: 2023-12-12
• Last Update Submitted: 2023-12-12
• Study First Posted: 2023-12-15
• Last Update Posted: 2023-12-15
• Primary Completion: 2024-01
• Study Completion: 2024-01-19

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Interference or not of activated charcoal in the measurement of protein S, antithrombin, and in the search for lupus anticoagulants.	Through study completion, an average of 6 months	This study compares the results of two diagnostic techniques (Thrombophilia work-up under direct oral anticoagulants (DOACs)), one using activated charcoal versus another not using it

Trial Locations

Locations (1)

Laboratoire d'Hématologie - CHU de Strasbourg - France; 🇫🇷 Strasbourg, France